Topic

Aetna (CVS Health)

A collection of 1076 issues

Myths vs. Facts: Getting Rezlidhia (olutasidenib) Covered by Aetna (CVS Health) in North Carolina

Answer Box: Fast Path to Rezlidhia Coverage in North Carolina Rezlidhia (olutasidenib) requires prior authorization from Aetna (CVS Health) for adults ≥18 with confirmed relapsed/refractory IDH1-mutated AML. Submit complete documentation including FDA-approved IDH1 mutation test results, treatment history, and oncologist prescription via CVS Caremark (1-855-344-0930) or Aetna provider portal.
5 min read

Work With Your Doctor to Get Defitelio (Defibrotide) Approved by Aetna (CVS Health) in California: Complete Guide With Forms and Appeals

Answer Box: Getting Defitelio (Defibrotide) Approved by Aetna (CVS Health) in California Defitelio (defibrotide) requires prior authorization from Aetna (CVS Health) for severe hepatic veno-occlusive disease (VOD/SOS) with organ dysfunction post-stem cell transplant. The fastest path to approval: (1) Have your transplant team submit the PA through Aetna'
6 min read

How to Get Vitrakvi (Larotrectinib) Covered by Aetna CVS Health in Illinois: PA Forms, Appeal Scripts & Timeline Guide

Quick Answer: Aetna CVS Health requires prior authorization for Vitrakvi (larotrectinib) with documented NTRK gene fusion testing and evidence of metastatic/unresectable disease. Submit PA via CVS Specialty at 1-888-267-3277 with molecular pathology report, oncologist notes, and prior therapy documentation. If denied, appeal within 180 days using medical necessity letter
5 min read

How to Get Helixate (Antihemophilic Factor, rFVIII) Covered by Aetna CVS Health in Michigan: Complete Coverage Guide with Appeals Process

Quick Answer: Getting Helixate Covered by Aetna CVS Health in Michigan Important Update: Helixate (antihemophilic factor, rFVIII) has been discontinued by the manufacturer. Aetna CVS Health now covers alternative factor VIII products like Kovaltry, Advate, and Jivi with prior authorization. First step: Contact your hematologist to select an alternative and
4 min read